IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances March 26, 2025 Read More »
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences March 20, 2025 Read More »
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida March 17, 2025 Read More »
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25” March 12, 2025 Read More »
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results” March 10, 2025 Read More »
IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection March 4, 2025 Read More »
IGC Pharma Expands Holiby™ Product Line with ‘Longevity’ and ‘Renew’ – Targeting the Multi-Billion-Dollar Anti-Aging Market February 20, 2025 Read More »
IGC Pharma Expands into $75 Billion Wellness Market with the Launch of Holiby™ February 11, 2025 Read More »
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer’s Disease January 28, 2025 Read More »
